Evidence map›Paper›PMID 34756614›Full record

ReviewVaccine2023

The immediate impact of the COVID-19 pandemic on polio immunization and surveillance activities.

Brent Burkholder, Zubair Wadood, Ahmed M Kassem, Derek Ehrhardt, Delayo Zomahoun

Open access · hybridAbstract readReview
In one paragraph

Review in Vaccine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Enterovirus Meningitis.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Vaccine Derived Poliovirus (VDPV).Le infezioni in medicina · 2023
    Review
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Brent BurkholderGlobal Public Health Consultant, 834 Miller Drive, Davis, CA 95616, United States. Electronic address: Burkholder834@gmail.com.
Zubair WadoodWHO Polio Eradication Division, Avenue Appia 20, 1211 Geneva, Switzerland. Electronic address: Wadoodm@who.int.
Ahmed M KassemGlobal Immunization Division, US Centers for Disease Control and Prevention, 1600 Clifton Road, NE Atlanta, GA 30333, United States. Electronic address: Yxo5@cdc.gov.
Derek EhrhardtGlobal Immunization Division, US Centers for Disease Control and Prevention, 1600 Clifton Road, NE Atlanta, GA 30333, United States. Electronic address: Fev1@cdc.gov.
Delayo ZomahounWHO Polio Eradication Division, Avenue Appia 20, 1211 Geneva, Switzerland. Electronic address: dzomahoun@who.int.
World Health Organization · CHCenters for Disease Control and Prevention · USNational Center for Immunization and Respiratory Diseases · US

Funding

World Health Organization 001
6 · The paper itself

Abstract

In addition to affecting individual health the COVID-19 pandemic has disrupted efforts to deliver essential health services around the world. In this article we present an overview of the immediate programmatic and epidemiologic impact of the pandemic on polio eradication as well as the adaptive strategic and operational measures taken by the Global Polio Eradication Initiative (GPEI) from March through September 2020. Shortly after the World Health Organization (WHO) declared a global pandemic on 11 March 2020, the GPEI initially redirected the programme's assets to tackle COVID-19 and suspended house-to-house supplementary immunization activities (SIAs) while also striving to continue essential poliovirus surveillance functions. From March to May 2020, 28 countries suspended a total of 62 polio vaccine SIAs. In spite of efforts to continue poliovirus surveillance, global acute flaccid paralysis (AFP) cases reported from January-July 2020 declined by 34% compared with the same period in 2019 along with decreases in the mean number of environment samples collected per active site in the critical areas of the African and Eastern Mediterranean regions. The GPEI recommended countries should resume planning and implementation of SIAs starting in July 2020 and released guidelines to ensure these could be done safely for front line workers and communities. By the end of September 2020, a total of 14 countries had implemented circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreak response vaccination campaigns and Afghanistan and Pakistan restarted SIAs to stop ongoing wild poliovirus type 1 (WPV1) transmission. The longer-term impacts of disruptions to eradication efforts remain to be determined, especially in terms of the effect on poliovirus epidemiology. Adapting to the pandemic situation has imposed new considerations on program implementation and demonstrated not only GPEI's contribution to global health security, but also identified potential opportunities for coordinated approaches across immunization and health services.

Indexed as

COVID-19PoliomyelitisPoliovirusDisease EradicationHumansImmunization ProgramsPandemicsPoliovirus Vaccine, OralPopulation SurveillanceVaccinationPoliovirus Vaccine, OralCirculating vaccine-derived poliovirusCOVID-19Global polio eradication

Identifiers

PMID34756614
PMCPMC8531002
OpenAlexW3210455023

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.